PBMCs have many applications in clinical development allowing centralized, large batch cell-based analysis. The method used to isolate PBMCs can have significant impacts on downstream analysis. Because of this relationship, great care must be taken to handle samples in a uniform and high-quality manner to avoid bias in downstream testing, especially when multiple sites are required. This webinar will provide an insight into the current best practices in PBMC isolation in the drug development process and examine new technologies for the future.
Brian Wile, PhD
Global Head, Scientific Affairs
Eurofins BioPharma Services